Olema Pharmaceuticals (OLMA) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Olema Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $24.7M of OLMA stock on the open market.
Get emailed when insiders cluster-buy stocks like OLMA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
OLMA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $291K | 2 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $7.4M | 12 |
| Q4 2025 | — | 0 | $17.0M | 11 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Olema Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $24.7M. 0 of 25 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 27SEC | Cyrus HarmonDirector | Sell | 12,500702,770 held (−2%) | $11.71 | $146K | -33.2% | — |
| Jul 27SEC | Cyrus HarmonDirector | Sell | 12,500715,270 held (−2%) | $11.58 | $145K | -32.5% | — |
| Mar 5SEC | Shawnte MitchellGeneral Counsel | Sell | 24,767233 held (−99%) | $24.25 | $601K | -67.8% | — |
| Mar 5SEC | Shawnte MitchellGeneral Counsel | Sell | 15,000 | $23.01 | $345K | -66.0% | — |
| Mar 5SEC | Shawnte MitchellGeneral Counsel | Sell | 233 | $24.69 | $6K | -68.3% | — |
| Jan 21SEC | Cyrus HarmonDirector | Sell | 10,000727,770 held (−1%) | $26.88 | $269K | -70.9% | — |
| Jan 16SEC | Cyrus HarmonDirector | Sell | 3,489737,770 held (−0%) | $29.12 | $102K | -73.1% | — |
| Jan 15SEC | Shane William Charles KovacsCh. Operating & Financial Off. | Sell | 100,000139,727 held (−42%) | $28.73 | $2.9M | -72.8% | — |
| Jan 15SEC | Shane William Charles KovacsCh. Operating & Financial Off. | Sell | 3,822239,727 held (−2%) | $28.01 | $107K | -72.1% | — |
| Jan 14SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 49,800542,961 held (−8%) | $27.60 | $1.4M | -71.7% | — |
| Jan 14SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 35,003542,761 held (−6%) | $28.99 | $1.0M | -73.0% | — |
| Jan 14SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 14,997577,764 held (−3%) | $28.60 | $429K | -72.7% | — |
| Jan 14SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 10,000144,846 held (−6%) | $28.34 | $283K | -72.4% | — |
| Jan 14SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 200542,761 held (−0%) | $28.49 | $6K | -72.6% | — |
| Dec 29SEC | Cyrus HarmonDirector | Sell | 2,881741,259 held (−0%) | $28.53 | $82K | -72.6% | — |
| Dec 23SEC | Ian T ClarkDirector | Sell | 193,05641,840 held (−82%) | $29.71 | $5.7M | -73.7% | — |
| Dec 23SEC | Naseem ZojwallaChief Medical Officer | Sell | 100,00053,997 held (−65%) | $28.04 | $2.8M | -72.1% | — |
| Dec 23SEC | Naseem ZojwallaChief Medical Officer | Sell | 99,5094,488 held (−96%) | $27.66 | $2.8M | -71.7% | — |
| Dec 23SEC | Naseem ZojwallaChief Medical Officer | Sell | 57,079116,918 held (−33%) | $28.03 | $1.6M | -72.1% | — |
| Dec 23SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 43,729557,927 held (−7%) | $30.40 | $1.3M | -74.3% | — |
| Dec 23SEC | Ian T ClarkDirector | Sell | 41,840 | $30.48 | $1.3M | -74.3% | — |
| Dec 23SEC | Ian T ClarkDirector | Sell | 29,904234,896 held (−11%) | $28.83 | $862K | -72.9% | — |
| Dec 23SEC | Naseem ZojwallaChief Medical Officer | Sell | 12,921103,997 held (−11%) | $28.93 | $374K | -73.0% | — |
| Dec 23SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 6,046551,881 held (−1%) | $31.39 | $190K | -75.1% | — |
| Dec 23SEC | David C. MylesCh. Discov. & Non-Clin Dev Off | Sell | 1,225601,656 held (−0%) | $28.08 | $34K | -72.2% | — |
Insiders at Olema Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Ian T ClarkDirector | — | $7.9M | Dec 23, 2025 | — |
| Naseem ZojwallaChief Medical Officer | — | $7.5M | Dec 23, 2025 | — |
| David C. MylesCh. Discov. & Non-Clin Dev Off | — | $4.7M | Jan 14, 2026 | — |
| Shane William Charles KovacsCh. Operating & Financial Off. | — | $3.0M | Jan 15, 2026 | — |
| Shawnte MitchellGeneral Counsel | — | $952K | Mar 5, 2026 | — |
| Cyrus HarmonDirector | — | $744K | Jul 27, 2026 | — |
OLMA stock: common questions
Are Olema Pharmaceuticals, Inc. insiders buying OLMA stock?
In the past 12 months, 0 insiders reported open-market purchases of OLMA worth $0.
Are Olema Pharmaceuticals, Inc. insiders selling OLMA stock?
6 insiders reported sales worth $24.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is OLMA's 52-week range?
Over the past year OLMA has traded between $7.77 and $35.83. It last closed at $7.82 on Oct 9, 2026.